| Literature DB >> 31572463 |
Anja Šoštarič1, Barbara Jenko2, Nada Rotovnik Kozjek2,3, Darja Ovijač1, Dušan Šuput4, Irina Milisav1,4, Vita Dolžan2.
Abstract
INTRODUCTION: Metabolic syndrome and associated diseases are a global health problem. Detection of early metabolic modifications that may lead to metabolic syndrome would enable timely introduction of preventive lifestyle modifications.Entities:
Keywords: anthropometry; exercise; metabolic syndrome; nutrition; young adults
Year: 2019 PMID: 31572463 PMCID: PMC6764305 DOI: 10.5114/aoms.2019.87462
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.318
MeS criteria. For MeS diagnosis 3 of the following criteria must be fulfilled (WHO criteria: insulin resistance criterion and 2 others). The individuals with the values above the most stringent threshold of measured criteria (bolded) were assumed to have the higher MeS burden (B-MeS) in this study
| Criteria | Anthropometric | Triglycerides | HDL-C | BP | FG | UAE |
|---|---|---|---|---|---|---|
| WHO, 1998 | ≥ 150 mg/dl (1.7 mmol/l) | < 35 mg/dl male (0.9 mmol/l) | ≥ 140/90 mm Hg, medication | < 110 mg/dl (6.1 mmol/l), T2DM, impaired glucose tolerance | ≥ 20 μg/min | |
| ATP-III, 2001 | WC > 102 male | ≥ 150 mg/dl (1.7 mmol/l) | < 40 mg/dl (1 mmol/l) male | ≥ 110 mg/dl (6.1 mmol/l) | / | |
| IDF | ≥ 150 mg/dl (1.7 mmol/l) medication | < 40 mg/dl (1 mmol/l) male | ≥ 100 mg/dl (5.6 mmol/l), T2DM | / | ||
| Consensus, 2009 | WC cut-off population and country specific | ≥ 150 mg/dl (1.7 mmol/l) medication | < 40 mg/dl (1 mmol/l) male | ≥ 130/85 mm Hg, drug treatment | ≥ 100 mg/dl (5.6 mmol/l), drug treatment | / |
BP – blood pressure, FG – fasting glucose, UAE – urinary albumin excretion, WC – waist circumference, W/H – waist-to-hip ratio, ATP-III – National Cholesterol Education Program (NCEP) Adult Treatment Panel III, Consensus – consensus between IDF-AHA/National Heart Lung and Blood Institute, IDF – International Diabetes Federation, WHO – World Health Organization.
Figure 1Two-compartment body measurements in participants with and without metabolic syndrome burden (B-MeS). A, C – body composition measured by single frequency BIA. D – amounts of visceral fat. B – number of participants with self-perception of being overweight versus the number of participants with the BMI equal to or above 25 kg/m2. The amounts of FFM above and below the population’s median (29.2%) are indicated in light and dark grey, respectively
The thin line indicates the median value in box and whisker plots; *statistical significance. FFM – fat free mass, FM – fat mass, AU – arbitrary units, B-MeS – metabolic syndrome burden.
Figure 2Anthropometric measurements in participants with and without the metabolic syndrome burden
The thin line indicates the median value; *statistical significance; BMI – body mass index, BP – blood pressure.
Figure 3Lifestyle indicators in participants with and without the metabolic syndrome burden
The thin line indicates the median value.
Polymorphisms of genes encoding the NRLP3 inflammasome (CARD8, NALP3) and of antioxidant enzymes (CAT: catalase, GPX1: glutathione peroxidase 1, SOD2: superoxide dismutase 2)
| Polymorphism | Genotype | B-MeS ( | Non-B-MeS ( | OR (95% CI) | |
|---|---|---|---|---|---|
| AA | 14 | 36 | 0.45 | 1.29 (0.66–2.52) | |
| CC | 32 | 60 | 0.22 | 0.27 (0.14–1.60) | |
| GG | 19 | 37 | 0.53 | 0.80 (0.39–1.57) | |
| CC | 13 | 37 | 0.45 | 1.29 (0.66–2.52) | |
| CC | 11 | 15 | 0.15 | 0.64 (0.34–1.17) |
Figure 4Laboratory parameters in participants with and without the metabolic syndrome burden
The thin line indicates the median value; *statistical significance.